TLRY · Tilray Brands, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 2, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 2, 2025.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $63.4M | fiscal 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 29% | fiscal 2026 | — |
| Adjusted net income non-GAAP | $12.2M | fiscal 2026 | — |
| Adjusted net income per share non-GAAP | $0.11 | fiscal 2026 | — |
| Cannabis adjusted gross margin (excluding PPA step-up) non-GAAP | 40% | For the year ended May 31, 2026 | — |
| Cash flow from operations, excluding working capital | $18.2M | fiscal year ended May 31, 2026 | — |
| Cash, restricted cash and Marketable Securities non-GAAP | $235M | fiscal year ended May 31, 2026 | — |
| Net Debt non-GAAP | $0.7M | fiscal year ended May 31, 2026 | — |
| Wellness gross margin | 33% | For the year ended May 31, 2026 | — |
| Adjusted cash operating income non-GAAP | $4M | Q3 Fiscal 2026 | — |
| Adjusted cash operating income (loss) non-GAAP | $17.75M | the nine months ended February 28, 2026 | — |
| Adjusted free cash flow non-GAAP | -$42.64M | the nine months ended February 28, 2026 | — |
| Adjusted gross profit non-GAAP | $174.55M | the nine months ended February 28, 2025 | — |
| Adjusted net income (loss) non-GAAP | $4.4M | the nine months ended February 28, 2026 | — |
| Adjusted net income (loss) per share non-GAAP | $0.02 | Q3 Fiscal 2026 | — |
| Free cash flow non-GAAP | -$52.86M | the nine months ended February 28, 2026 | — |
| Net cash position non-GAAP | $3.5M | Q3 Fiscal 2026 | — |
|
|
|||
| Adjusted net income excluding non-cash income tax charges non-GAAP | $1.6M | the second quarter | — |
| Cash and marketable securities non-GAAP | $291.6M | the second quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLRY
this stock
Tilray Brands, Inc.
|
$642.88M | -46.0% | +11.5% | — | 13.5% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.25B | +17.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.94B | +3.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.98B | +0.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 2, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLRY | +9.2% | +21.1% | -33.2% | +7.5% | -46.0% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | +9.4% | +17.7% | -44.9% | +5.0% | -58.3% |